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Many anticoagulant drugs inhibiting proteins of the coagulation cascade have been developed. The main
targets of anticoagulant drugs are thrombin and factor Xa; inhibiting these factors delays thrombus
growth, thus preventing thrombosis while increasing bleeding risk. A balance between thrombosis and
bleeding is ensured in the ‘therapeutic window’ of the anticoagulant drug concentration range. Novel
anticoagulant drugs and combinations thereof are being developed. We rank coagulation factors as
potential anticoagulant drug targets in combination with thrombin inhibitors, aptamer HD1 and biva-
lirudin, providing a background for several promising dual target treatment strategies.
The thrombin generation test was used to assess the whole coagulation cascade in normal and factor-
deﬁcient human blood plasma. Potential therapeutic windows were estimated for coagulation factors,
ranking them as targets for anticoagulant drugs. Thrombin and factor Xa have been revealed as the most
promising targets, which fully agrees with the current drug development strategy. Inhibitors of factors Va
and VIIa are expected to have narrow therapeutic windows. Inhibitors of factors VIIIa and IXa are ex-
pected to have a moderate anticoagulant effect. Factors XI and XII are poor targets for anticoagulant
drugs. Compared with plasma that is deﬁcient in factor II, the thrombin inhibitors bivalirudin and ap-
tamer HD1 had increased activity. Both inhibitors were tested in deﬁcient plasma providing a model of
potential drug combination. The most promising combinations were anti-thrombin with anti-V/Va and
also anti-thrombin with anti-IX/IXa. Each combination had an incremental dose-effect dependence that
is promising from the standpoint of the therapeutic window.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The coagulation cascade together with platelets provide
thrombus formation in several seconds after a vessel injury. The
coagulation cascade yields ﬁbrin ﬁbers that tighten the plug
formed from aggregating platelets. Both processes are tightly
regulated by several feedback mechanisms (accelerating as well as
inhibitory) to ensure a controlled, prompt response. Genetic al-
terations, inﬂammation, obesity, cancer, immobilization, and other
causes lead to conditions of excessive thrombus formation [1–4].
Oral anticoagulant drugs and platelet inhibitors have been devel-
oped to prevent thrombotic events in high-risk patients. Par-
enteral anticoagulant drugs have been developed for surgical
procedures [3,5,6]. The causes of thrombosis are manifold and
treatment thus requires adapted approaches employing distinct
medications and combinations thereof. Therapeutic combinations
of several platelet inhibitors and also combinations of plateletB.V. This is an open access article u
ova).inhibitors with an anticoagulant drug have currently passed clin-
ical trials [3,7–9]. Other combinations still have to be explored
providing safer and more efﬁcient thrombosis treatment.
The coagulation cascade is triggered with the tissue factor that
is exposed upon vessel damage. The tissue factor triggers factor VII
activation to factor VIIa, which in turn catalyzes the activation of
factor X to factor Xa, which catalyzes the conversion of pro-
thrombin into thrombin. Thrombin and also factors VIIa and Xa
catalyze several positive regulatory loops that signiﬁcantly accel-
erate thrombin generation (see Fig. 1). The main function of
thrombin in vivo is to catalyze the conversion of ﬁbrinogen into
ﬁbrin, which spontaneously associates into a net of ﬁbrin ﬁbers.
Excessive thrombin is mainly neutralized by antithrombin III, a
serpin-family protein acting like a suicide substrate. A set of in-
hibitors is responsible for disabling the cascade after a proper ﬁ-
brin ﬁber net is formed; among them are heparin cofactor II in-
hibiting thrombin, activated protein C with protein S inhibiting
factors Va and VIIIa, as well as TFPI inhibiting the factor Xa-de-
pendent activation of factor VII [11–13].
The thrombin generation test (TGT) is a sophisticated techniquender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. The coagulation cascade is a sophisticated regulatory network controlling the formation of ﬁbrin ﬁber. Tissue factor triggers coagulation under vessel damage,
whereas factor XII induces supplementary contact activation intrinsic pathway. HK – high molecular weight kininogen, PL – phospholipid surface, TM – thrombomodulin,
APC – activated protein C, TFPI – tissue factor pathway inhibitor. The scheme is derived from a diagram from Enzyme Research Laboratories [10].
Fig. 2. Thrombin generation in normal and deﬁcient plasma. A – TGT parameters; B – thrombin generation in normal, factor II-, factor V-, and factor VII-deﬁcient plasma; C –
thrombin generation in normal, factor VIII-, factor IX-, and factor X-deﬁcient plasma; D – thrombin generation in normal, factor XI-, and factor XII-deﬁcient plasma.
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time tracing of thrombin produced in a blood plasma sample. The
technique traces thrombin generation and its subsequent in-
activation using a ﬂuorogenic substrate. The thrombin generation
proﬁle is sensitive to anticoagulant drugs and hemophilia-relateddisorders and is a sharp tool for diagnostics and for research issues
[14–19]. For example, the TGT has recently been used to test
therapeutic combinations of edoxaban, a factor Xa inhibitor, with
the platelet inhibitors clopidogrel and ticagrelor [18].
A wide variety of thrombin inhibitors have been developed,
Fig. 3. Time to peak and peak thrombin concentration in plasma with different factor content: A – factor II, B – factor V, C – factor VII, and D – factor X deﬁcient plasma (no
peak – time to peak exceeds 240 min).
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aptamer HD1 are short-acting anticoagulant drugs for the in-
travenous administration during surgical procedures. Bivalirudin is
a peptide of 20 amino acids, which binds thrombin through the
interaction with both the active site and the ﬁbrinogen-binding
site [21,22], whereas the aptamer HD1 is a short DNA of 15 nu-
cleotides which is structured in a guanine quadruplex, and binds
thrombin through ﬁbrinogen-binding site only [23,24]. Both an-
ticoagulant drugs are highly speciﬁc and have linear dose-effect
dependencies at micromolar concentrations in blood plasma
[24,25].
The development of dual targeting therapy based on direct
inhibitors of thrombin and of some other coagulation factors could
be beneﬁcial, providing a decrease of therapeutic doses (syner-
gism) and a decrease of bleeding rates (non-linear dose-effect
dependence). As a ﬁrst estimation, we have used the TGT to assess
anticoagulant effect of thrombin inhibitors, bivalirudin and apta-
mer HD1, on blood plasma with coagulation factor deﬁciency. As a
result, we have estimated the inhibitory capacity of potential an-
ticoagulant drug combinations providing a background for the
development of novel dual target treatment strategies.2. Materials and methods
Inorganic salts and Tris were purchased from MP Biomedicals
(France). Bivalirudin triﬂuoroacetate was purchased from Selleck
Chemicals, USA; DNA aptamer HD1, 5′-ggttggtgtggttgg-3′, wassynthesized by Evrogene (Russian Federation). Standard platelet-
poor human plasma (normal plasma) and all deﬁcient human
plasma were purchased from Siemens (Germany). The Techno-
thrombins TGA Kit, the whole set of reagents for the TGT, was
purchased from Technoclone (Austria).
2.1. Thrombin generation test
An Inﬁnites 200 Pro microplate reader equipped with ﬂuor-
escent and thermostatic modules (Tecan GmbH, Switzerland) was
used to perform the TGT. The calibration procedure and mea-
surements were performed according to the manufacturer's pro-
tocol. For the control experiments, 40 μl of normal plasma was
placed in a well of a 96-well microliter plate (Greiner Bio-One,
USA), 50 μl of ﬂuorogenic substrate solution with calcium cations
was then added, and 10 μl of trigger was ﬁnally added to start the
coagulation cascade. The microplate reader was thermostatically
controlled at 37 °C. The time intervals between measurements
were 1 min, and the respective excitation and emission wave-
lengths were 360 nm and 460 nm. The experiment lasted until the
ﬂuorescence plateau was reached. The RCL reagent was used as a
trigger containing tissue factor embedded in phospholipid micro-
vesicles. Each measurement was performed at least three times.
Immunodepleted deﬁcient human plasma was used to assess
the effect of the particular factor deﬁciency. The manufacturer
declared a particular factor-deﬁcient human plasma to have r1%
of the activity of the particular factor. Mixtures of normal plasma
(approx. 100% content of the factor) and factor-deﬁcient plasma
Fig. 4. Time to peak and peak thrombin concentration in plasma with different factor content: A – factor VIII-, B – factor IX-, C – factor XI-, and D – factor XII-deﬁcient
plasma.
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particular factor contents of 0%, 2%, 10%, 25%, 50%, and 100%. Each
mixture was tested as described above. Plasma deﬁcient in one of
the factors, II, V, VII, VIII, IX, X, XI, and XII, was tested.
The thrombin inhibitors bivalirudin and DNA aptamer HD1
were tested in normal, deﬁcient plasma, and their mixtures de-
scribed above. The inhibitor was added to the plasma sample in a
volume of r4 μl to minimize alterations of the reaction mixture
volume. To assemble the spatial structure of DNA aptamer HD1, its
solution in 10 mM KCl was heated for 5 min at 95 °C and cooled to
room temperature before each experiment. To study the inhibitory
effects on normal plasma, the ﬁnal inhibitor concentration in
plasma was set in a range of 0.5–10 mM. To study the inhibitory
effects on deﬁcient plasma, the ﬁnal concentration was 2 mM for
bivalirudin and 4 mM for the DNA aptamer HD1. Each plasma
sample was tested with the inhibitor as described above.
2.2. Data treatment
Thrombin generation curves were derived from the ﬂuores-
cence curves and parameterized using the Technothrombins TGA
Evaluation Software (Technoclone, Austria). All subsequent data
manipulations including statistical analysis to calculate means and
standard deviations from three individual measurements were
performed using Origin 8.1 (OriginLab, USA). The same software
was used to construct all graphs.3. Results and discussion
3.1. Thrombin generation in deﬁcient plasma
Data treatment of the TGT yields a dependence of thrombin
concentration on reaction time (Fig. 2A). The curve represents two
main processes: thrombin generation de novo and its subsequent
complete inactivation by cascade inhibitors. The curve can be de-
scribed by a set of characteristic parameters:
1. Lag time is the time of generating the ﬁrst thrombin amounts
(about 2–10 nM) after cascade triggering.
2. Peak thrombin concentration is the maximum enzyme con-
centration resulting from a balance between the thrombin
generation and inactivation processes.
3. Time to peak corresponds to the time of maximum thrombin
concentration.
4. Velocity index represents the effective rate of thrombin gen-
eration between lag time and time to peak.
5. Endogenous thrombin potential (ETP) is the area under the
curve; ETP reﬂects the total enzymatic work of thrombin, which
depends on the thrombin amount and its lifetime in plasma.
Poor coagulation is characterized by decreased peak thrombin
concentration, velocity index, and ETP, while lag time and time to
peak increase.
In this study, we characterized normal and eight deﬁcient
Table 1
TGT parameters in plasma with factor content varied from 100% (normal plasma) to
0% (factor deﬁcient plasma). The values are expressed in percentages from the
values for normal plasma. n.m. – not measurable.
Deﬁcient
factor
TGT parameters Amounts of normal plasma
100% 50% 25% 10% 2% 0%
Factor II Lag time 100 90 100 110 150 380
Peak thrombin
concentration
100 62 41 18 4 n.m.
Time to peak 100 100 120 130 100 n.m.
ETP 100 79 58 24 3 n.m.
Factor V Lag time 100 120 120 140 170 400
Peak thrombin
concentration
100 100 120 110 140 4
Time to peak 100 110 110 90 110 240
ETP 100 110 130 110 120 3
Factor VII Lag time 100 70 75 95 130 190
Peak thrombin
concentration
100 190 170 180 190 210
Time to peak 100 80 85 95 100 130
ETP 100 150 150 160 160 170
Factor VIII Lag time 100 60 60 60 68 75
Peak thrombin
concentration
100 150 150 110 86 41
Time to peak 100 83 84 91 103 180
ETP 100 140 150 135 116 70
Factor IX Lag time 100 70 70 66 73 85
Peak thrombin
concentration
100 120 130 77 54 39
Time to peak 100 90 93 102 120 130
ETP 100 120 130 90 82 67
Factor X Lag time 100 92 106 120 270 490
Peak thrombin
concentration
100 100 90 66 30 n.m.
Time to peak 100 95 100 120 180 n.m.
ETP 100 108 105 90 41 n.m.
Factor XI Lag time 100 68 59 65 76 66
Peak thrombin
concentration
100 120 100 120 110 120
Time to peak 100 110 100 110 100 120
ETP 100 120 110 135 120 140
Factor XII Lag time 100 58 55 56 53 65
Peak thrombin
concentration
100 140 140 170 210 150
Time to peak 100 100 85 120 100 110
ETP 100 120 120 150 150 130
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viously, Duchemin et al. [26] published results for the thrombin
generation in deﬁcient plasma using calibrated automated
thrombography. The main difference between these two assays is
a trigger. Duchemin et al. used 1 or 5 pM of tissue factor and 4 mM
of phospholipid vesicles [26]. Technothrombins reagent differs in
ten-fold higher tissue factor content [27]. Both assays provide si-
milar TGT results in normal plasma [28]. Here, we provide data for
the comparison of two assays in deﬁcient plasma.
Deﬁcient plasma were produced using immunodepletion that
could affect the contents of some non-target coagulation factors,
providing some additional effect on thrombin generation. This
gives one more reason for the careful comparison of new data with
results published previously.Prothrombin (factor II) and factor X are the most critical pro-
teins for thrombin generation because the key reaction comprises
prothrombin cleavage by factor Xa. The absence of either factor II
or factor X leads to the absence of thrombin (Fig. 2B and C). An-
other protein with a great impact on thrombin generation is factor
V, a cofactor of prothrombin cleavage with factor Xa; its absence
dramatically decreases thrombin generation (Fig. 2B).
The absence of either factor VIII or factor IX has a moderate
effect on thrombin generation, cutting peak thrombin concentra-
tion by more than half and slightly increasing the time to peak
(Fig. 2C). Factors VIII and IX participate in the additional activation
pathway of factor X.
Factors XI and XII have a low impact on thrombin generation as
they are unnecessary for tissue-factor-triggered coagulation
(Fig. 2D). All the data agree with the ﬁrst experiments using the
TGT on deﬁcient plasmas [26].
Thrombin generation in factor VII deﬁcient plasma (Fig. 2B)
differs from the data of Duchemin et al. [26]. Factor VII is crucial
for tissue-factor-triggered thrombin generation because it is the
protein that interacts with the tissue factor, and the tissue factor–
factor VIIa complex activates factor X. A high level of thrombin
generation in factor VII deﬁcient plasma can be explained if the
residual content of factor VII in the immunodepleted plasma suf-
ﬁces to trigger the cascade under a high tissue factor concentra-
tion. Retardation of cascade triggering is shownwith a doubled lag
time, while the lag times of factor VIII- and factor IX-deﬁcient
plasma are the same as in normal plasma (Fig. 2B and C).
In contrast, Duchemin et al. [26] used a low tissue factor con-
centration to trigger the deﬁcient plasma that yielded a sig-
niﬁcantly weaker thrombin generation. Hence, high trigger
amounts could compensate for a low factor VII concentration and
yield normal thrombin generation. These data are in agreement
with van't Veer et al. [29], who showed that 100 pM of factor VIIa
is sufﬁcient for thrombin generation under a tissue factor con-
centration of 100 pM, but not 10 pM. These results highlight the
ability of the cascade to function properly, even under the con-
siderable deﬁciency of some proteins.
More detailed experiments were conducted to assess the de-
pendence of thrombin generation on the particular factor content.
Normal plasma (approx. 100% of the particular factor) and factor-
deﬁcient plasma (approx. 0% of the particular factor) were mixed,
yielding a set of samples with nominal 0%, 2%, 10%, 25%, 50%, and
100% content of the particular factor. Peak thrombin concentration
and time to peak were chosen as the most indicative parameters;
their alteration upon changing the particular factor content is
shown in Figs. 3 and 4. The whole set of data is listed in Table 1.
The decrease in prothrombin content linearly reduced peak
thrombin concentration, while time to peak drastically increased
in the sample with 0% prothrombin (Fig. 3A). Factor X deﬁciency
had a similar effect, but the curve of peak thrombin concentration
was nonlinear, and its major curvature was observed in the 0–25%
range of factor X content (Fig. 3D). The factor V curve was also
nonlinear with major changes in the 0–2% range of factor V con-
tent (Fig. 3B). Extremely low peak thrombin concentration
corresponds to only 2.5-fold increase of time to peak. Factor VII
deﬁciency slightly increased time to peak and peak thrombin
concentration (Fig. 3C).
Factors VIII and IX promote factor X activation. Deﬁciency of
these factors decreased peak thrombin concentration 2–3-fold in
the 0–25% range of factor content. Time to peak was doubled in
the case of factor VIII deﬁciency; factor IX deﬁciency had a weaker
effect on the parameter (Fig. 4A and B). Both factor XI and XII had
negligible effects on peak thrombin concentration and time to
peak in all concentration ranges (Fig. 4C and D).
A low content of the key coagulation factors except pro-
thrombin decreased peak thrombin concentration nonlinearly
Fig. 5. Thrombin generation in normal plasma in the presence of thrombin inhibitors: A, B – bivalirudin; C, D – aptamer HD1.
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linear dependence. Time to peak increased abruptly at extremely
low factor content.
3.2. Thrombin generation in plasma with thrombin inhibitors
Bivalirudin and the DNA aptamer HD1 represent promising
biodegradable classes of thrombin inhibitors with high speciﬁcity
and low toxicity. These inhibitors affected thrombin generation
differently. Both inhibitors increased lag time and time to peak in
normal plasma; the effect of bivalirudin was approximately ﬁve
times greater than that of the aptamer (Fig. 5). Bivalirudin sub-
stantially delayed the beginning of thrombin generation; just after
the ﬁrst thrombin amounts appeared, bulk thrombin amounts
formed. Peak thrombin concentration was increased in the sam-
ples with bivalirudin, while ETP decreased slightly. These para-
meters indicate a steepening of the thrombin generation curve;
the same amount of thrombin is produced in a shorter time per-
iod. Similar results were previously published by Tanaka et al. [17].
The aptamer inhibited the overall process, resulting in a decrease
of ETP, peak thrombin concentration, and velocity index, as well as
the increase of lag time and time to peak (Fig. 5C and D). In con-
trast, partial factor II deﬁciency decreased ETP, peak thrombin
concentration, and velocity index, while lag time and time to peak
were affected only in the total absence of prothrombin (Fig. 3A).These inhibitors affect thrombin generation differently, and
both differ from factor II deﬁcient plasma in the TGT. These data
indicate that thrombin-inhibitor complexes actively participate in
protein–protein interactions forming nonproductive interactomes
and thus provide an additional inhibitory action. Some conﬁrma-
tion could be found in Danforth et al. [30]; a 60% content of either
factor V or IX or X alone did not increase time to peak, while 60%
content of all three factors increased time to peak by 1.5-fold.
Moderate inhibition of several coagulation factors could thus yield
a pronounced effect. Studying the effect of thrombin inhibitors on
deﬁcient plasmas could elucidate thrombin feedbacks that are
inhibited with aptamer and/or bivalirudin.
3.3. Thrombin generation in deﬁcient plasmas with thrombin
inhibitors
Bivalirudin and DNA aptamer HD1 were tested in factor deﬁ-
cient plasma with a nominal content of the particular factor of 0%,
2%, 10%, 25%, 50%, and 100%. The two inhibitors affected the TGT
parameters differently. Time to peak was chosen as the main
parameter for the comparison because it was increased by both
inhibitors, while it was unchanged for most of the plasma samples
and increased drastically in some samples with 0% nominal con-
tent of the particular factor.
Thrombin inhibitors highlighted the ranking of the coagulation
Fig. 6. Thrombin generation inhibited with bivalirudin and aptamer HD1 with different factor contents: A – factor II-, B – factor V-, C – factor VII-, and D – factor X-deﬁcient
plasma (no peak – time to peak exceeds 240 min).
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generation in the samples with a low content of factors II, V, VII,
and X (Fig. 6). All of these factors are essential for tissue-factor-
triggered coagulation. The most interesting results were obtained
for plasma deﬁcient in factors V or VII. Both plasma with a parti-
cular factor content of about o1% had delayed thrombin genera-
tion (control experiments), and bivalirudin and aptamer com-
pletely inhibited thrombin generation in these plasma. The effects
of the thrombin inhibitors on factor V-deﬁcient plasma were the
most pronounced among all other samples. A possible reason for
this phenomenon could be competition between the inhibitor and
factor V for the thrombin exosite I. This exosite is necessary for
factor V binding and activation with thrombin [31]. The aptamer
binds the same thrombin exosite I; moreover, it binds the pro-
exosite I of prothrombin. The latter binding mode leads to com-
petition with factor Va in the prothrombin activation complex and
thus inhibits thrombin generation [23]. These multilevel inhibitory
actions of the aptamer could be a reason for the obvious difference
between the time-to-peak alteration in factor II deﬁcient plasma
and in normal plasma with the aptamer. Bivalirudin also targets
thrombin exosite I [21] and potentially could inhibit factor V ac-
tivation with thrombin, being a more efﬁcient anticoagulant drug
than the aptamer.
Factor VIII is also activated by thrombin, and this process could
be inhibited by inhibitors of the thrombin exosite I. However, adeﬁciency of factor VIII per se, as well as its combination with
thrombin inhibitors, affected thrombin generation only moder-
ately (Fig. 7A). Similar effects were observed for factor IX-deﬁcient
plasma; bivalirudin inhibited thrombin generation more efﬁciently
than the aptamer (Fig. 7B).
There were no statistically signiﬁcant differences in the sam-
ples with different contents of factors XI and XII (Fig. 7C and D).
Both factors had minor effects on tissue-factor-triggered coagula-
tion, and the thrombin inhibitors did not yield any substantial
changes in thrombin generation in the presence of a deﬁciency of
these factors.
3.4. Potential anticoagulant drugs for dual targeting treatment
Plasma deﬁcient in a particular factor is a model system for the
anticoagulant action if we suppose that the inhibitor turns off all
factor activities being an equivalent to the absence of the factor.
But thrombin inhibitors provide an example of a multilevel in-
hibitory action. Bivalirudin and DNA aptamer HD1 bind thrombin
exosite I and inhibit protein–protein interactions that are medi-
ated by this site. Nevertheless, the thrombin-inhibitor complex
still uses other thrombin sites for protein–protein interactions
forming nonproductive interactomes. Free thrombin in fact com-
petes with the thrombin-inhibitor complex for binding factors V
and VIII. Another possibility for multilevel inhibition is the binding
Fig. 7. Thrombin generation inhibited with bivalirudin and aptamer HD1 with different factor content: A – factor VIII-, B – factor IX-, C – factor XI-, and D – factor XII-
deﬁcient plasma.
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Considering a simple model of factor inhibition, we could rank
coagulation proteins using the TGT with tissue factor as the trig-
ger: (1) factors that are required for thrombin generation (II, V, VII,
and X), (2) factors that are signiﬁcant for thrombin generation (VIII
and IX), and (3) factors that are irrelevant for tissue-factor-trig-
gered thrombin generation (XI and XII). The ﬁrst and second
groups are potential anticoagulant drug targets. Inhibitors of
proteins in the ﬁrst group could totally prevent thrombin gen-
eration. Inhibitors of factors II/IIa and X/Xa could provide any ex-
tent of thrombin generation decrease, potentially yielding a wide
therapeutic window. While inhibitors of factors V/Va and VII/VIIa
could provide an “all or none” effect, they have limited therapeutic
value because their therapeutic window is potentially narrow.
Inhibitors of proteins in the second group could provide only a 2–
3-fold decrease of thrombin generation; inhibition of factors IX/
IXa is expected to impact thrombin generation more than inhibi-
tion of factors VIII/VIIIa. The potential therapeutic window is
questionable because the efﬁcacy of the inhibitors is initially re-
stricted. These conclusions fully agree with the current drug
market: all direct anticoagulant drugs target either factor Xa or
thrombin (IIa); the RNA aptamer to factor IXa reached Phase III of
the clinical trials [32]. Inhibitors of other factors stand aside, as
they are currently in research and development.
Bivalirudin and aptamer HD1 demonstrated that inhibitors canexhibit a multilevel inhibitory mode. This ability is a result of two
circumstances: (1) thrombin is involved in multiple feedbacks, and
(2) the ligand could bind prothrombin, inhibiting its conversion to
the thrombin. The ﬁrst circumstance is unique to thrombin, but
the second could be used to design new inhibitors of other factors.
Although anticoagulant drugs function in various ways, some
anticoagulant drug combinations could be evaluated. We have
assessed possible combinations based only on thrombin inhibitors.
The most potent and promising combination could be created by
combining thrombin and factor V/Va inhibitors; pronounced sy-
nergetic effects are expected in the case of partial inhibition of
factor V with a wide therapeutic window. Combining thrombin
inhibitors with inhibitors of factors VII/VIIa and X/Xa seems less
promising because there is no effect plateau; the TGT parameters
change rapidly as the factor content decreases. Factor IX is espe-
cially interesting because its restricted effect on thrombin gen-
eration could be accentuated with thrombin inhibitors. This
combination could substantially decrease thrombin generation
without the risk of preventing it completely. This feature could be
extremely relevant for therapeutic applications. A thorough study
of real anticoagulant drug combinations will elucidate speciﬁc
features of the coagulation cascade functioning and help to ﬁnd
new, potent, and safe anticoagulant drug formulations.
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